Denmark-based Zealand Pharma has raised approximately DKr1.45bn ($212.5m) to fund the advancement of its obesity pipeline.
The money was raised by private placement and directed issue of 3,761,470 new shares, with the DKr1 nominal value of each share, to two US-based investment firms. The total placement represents approximately 6% of Zealand’s currently registered share capital, as per an 8 January press release.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,